Chugai Pharmaceutical Co., Ltd. Share Price
Stocks
4519
JP3519400000
Pharmaceuticals
OTC Markets Traded|
Delayed
Japan Exchange
06:15:25 02/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 6,851.00 JPY | -1.20% |
|
-2.84% | -16.89% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-18 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 11,409B 71.27B 61.48B 57.83B 52.68B 99.07B 6,764B 99.61B 684B 266B 3,441B 268B 262B | P/E 2026 * |
22.5x | P/E 2027 * | 19.6x |
|---|---|---|---|---|---|
| Enterprise Value | 10,498B 65.58B 56.57B 53.21B 48.48B 91.17B 6,224B 91.66B 629B 245B 3,166B 246B 241B | EV / Sales 2026 * |
7.56x | EV / Sales 2027 * | 6.71x |
| Free-Float |
38.12% | Yield 2026 * |
1.96% | Yield 2027 * | 2.24% |
Last Transcript : Chugai Pharmaceutical Co., Ltd.
| 1 day | -1.20% | ||
| 1 week | -2.84% | ||
| Current month | -0.90% | ||
| 1 month | +2.45% | ||
| 3 months | -10.07% | ||
| 6 months | -32.47% | ||
| Current year | -16.89% |
| 1 week | 6,814 |  | 7,054 |
| 1 month | 6,575 | | 7,229 |
| Current year | 6,575 | | 10,700 |
| 1 year | 6,250 | | 10,700 |
| 3 years | 4,197 | | 10,700 |
| 5 years | 3,191 | | 10,700 |
| 10 years | 1,003.33 | | 10,700 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 28/02/2021 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 27/03/2024 |
Shinya Takuma
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Fumio Tateishi
BRD | Director/Board Member | 77 | 28/02/2023 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 27/03/2024 |
Hideo Teramoto
BRD | Director/Board Member | 66 | 28/02/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.20% | -2.84% | +5.27% | +54.27% | 71.27B | |
| +0.28% | -5.97% | +58.34% | +108.22% | 1,034B | |
| +2.01% | -0.71% | +53.07% | +68.99% | 654B | |
| +1.39% | -2.18% | +23.57% | +75.43% | 459B | |
| -1.50% | -7.04% | +33.55% | +33.94% | 343B | |
| +6.25% | +2.04% | +28.97% | +46.57% | 307B | |
| -0.07% | -4.12% | +0.95% | +11.79% | 251B | |
| +1.92% | -0.93% | +52.28% | +70.67% | 237B | |
| +0.51% | -4.52% | -19.50% | -54.83% | 202B | |
| +2.45% | +0.77% | +32.71% | +95.59% | 186B | |
| Average | +1.33% | -2.61% | +26.92% | +51.06% | 374.29B | |
| Weighted average by Cap. | +1.58% | -3.25% | +37.77% | +66.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,388B 8.67B 7.48B 7.04B 6.41B 12.06B 823B 12.12B 83.19B 32.38B 419B 32.56B 31.85B | 1,529B 9.55B 8.24B 7.75B 7.06B 13.28B 906B 13.35B 91.61B 35.66B 461B 35.86B 35.08B |
| Net income | 506B 3.16B 2.73B 2.57B 2.34B 4.4B 300B 4.42B 30.34B 11.81B 153B 11.87B 11.62B | 583B 3.64B 3.14B 2.96B 2.69B 5.07B 346B 5.09B 34.96B 13.61B 176B 13.68B 13.39B |
| Net Debt | -910B -5.69B -4.9B -4.61B -4.2B -7.9B -540B -7.95B -54.54B -21.23B -274B -21.35B -20.88B | -1,151B -7.19B -6.2B -5.83B -5.31B -9.99B -682B -10.05B -68.96B -26.84B -347B -26.99B -26.41B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/09/26 | JP¥6,851.00 | -1.20% | 1,243,500 |
| 01/09/26 | JP¥6,934.00 | +0.30% | 1,623,100 |
| 31/08/26 | JP¥6,913.00 | -1.71% | 2,937,400 |
| 28/08/26 | JP¥7,033.00 | +1.24% | 1,982,400 |
| 27/08/26 | JP¥6,947.00 | -1.47% | 1,806,300 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
